Outset Medical, U.S. Renal Care Agree to Accelerate and Grow Home Dialysis

 Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, and U.S. Renal Care, the largest privately held kidney care provider in the United States, announced today a multi-year agreement to help accelerate home hemodialysis in the U.S.

Studies show patients with end-stage kidney disease (ESKD) are healthier mentally and physically dialyzing at home, more likely to be employed and maintain more control of their daily activities. Yet, just 3% of the ESKD population currently performs home hemodialysis, in large part due to historically complicated systems that made it too difficult to undertake or sustain. Under the multi-year agreement, U.S. Renal Care can utilize Outset’s Tablo Hemodialysis System as a home dialysis option throughout the 33 states in which it provides care. Patients dialyzing with Tablo report that the system is easy to learn and operate in their home. Expanding treatment options in the communities served by U.S. Renal Care will aid in meeting the growing demand of dialysis patients seeking treatment at home.

https://www.biospace.com/article/releases/outset-medical-and-u-s-renal-care-announce-multi-year-agreement-to-accelerate-and-grow-home-dialysis-across-the-u-s-/